Kaposi's sarcoma had been recognized as unique human cancer for a century before it
manifested as an AIDS-defining illness with a suspected infectious etiology. The discovery of …

Kaposi sarcoma (KS) remains a challenge. Its classic or Mediterranean form tends to be
benign. In transplant recipients it may be less so. As part of the AIDS pandemic, of which it …

Outcomes of kidney transplantation, in terms of graft and patient survival, have improved
over the past few decades, partly as a result of the introduction of new immunosuppressive …

Post‐transplant de novo malignancies are reviewed in three time periods:(i) the azathioprine
(AZA) era from 1962 to 1980–1981,(ii) the cyclosporine (CYA) era (1980 to present) in which …

While there have been many important advances in the study of Kaposi's sarcoma (KS), it
remains both a challenge and an enigma in many ways. Kaposi's original description of …

Recipients of liver transplantation (LT) have a higher overall risk (2‐3 times on average) of
develo** de novo malignancies than the general population, with standardized incidence …

Background Reduction of immunosuppression is considered a reasonable adjuvant
therapeutic strategy in solid‐organ transplant recipients experiencing multiple or high‐risk …

In response to recently published KDIGO (Kidney Disease: Improving Global Outcomes)
guidelines for the care of kidney transplant recipients (KTRs), the National Kidney …

Background: Overexpression of vascular endothelial growth factor (VEGF) correlates with
vascularity, metastasis, and proliferation in colorectal cancer but the role of its homologue …

Background Kaposi sarcoma (KS) occurs mainly in immunocompromised patients and is
strongly associated with infection with human herpesvirus 8 (HHV-8; also known as “KS …